TLX · ASX

Telix Pharmaceuticals Limited (ASX:TLX)

AU$30.12

 3.66 (13.832%)
ASX:Live
21/02/2025 04:10:56 PM
Volume Spike Short Term Trend - Long Recent Price upgrade Recent Earnings upgrade Near Resistance +14
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

TLX Overview

TLX Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Very Strong

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Weak

Growth

Earnings

Very Weak

Dividends

Very Strong

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About TLX

Website

Telix Pharmaceuticals Limited

Telephone

61.3.9093.3855

Address

North Melbourne Suite 401 55 Flemington Road Melbourne, Victoria (VIC) 3051

Description

Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

TLX Price Chart

Key Stats

Market Cap

AU$9.03B

PE

114.70

EV/EBITDA

72.7

Dividends Overview

DIV Yield

.0%

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 10.34 - 29.72

Trade Value (12mth)

AU$6,074,630.00

1 week

-2.29%

1 month

-0.11%

YTD

10.99%

1 year

140.55%

All time high

29.72

Key Fundamentals

EPS 3 yr Growth

-152.30%

EBITDA Margin

14.60%

Operating Cashflow

$70m

Free Cash Flow Return

N/A

ROIC

N/A

Interest Coverage

5.20

Quick Ratio

N/A

Other Data

Shares on Issue (Fully Dilluted)

332m

HALO Sector

Healthcare

Next Company Report Date

21-Feb-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

3.27

TLX Announcements

Latest Announcements

Date Announcements

20 February 25

Appendix 4E and 2024 Annual Report

×

Appendix 4E and 2024 Annual Report

20 February 25

2024 Full Year Results Announcement

×

2024 Full Year Results Announcement

20 February 25

2024 Full Year Results Presentation

×

2024 Full Year Results Presentation

20 February 25

Appendix 4G and 2024 Corporate Governance Statement

×

Appendix 4G and 2024 Corporate Governance Statement

13 February 25

Illuccix Approved in the United Kingdom

×

Illuccix Approved in the United Kingdom

11 February 25

Telix 2024 Full Year Results and Investor Webcast/Call

×

Telix 2024 Full Year Results and Investor Webcast/Call

31 January 25

Telix Completes Acquisition of Tx Assets, Biologics Platform

×

Telix Completes Acquisition of Tx Assets, Biologics Platform

31 January 25

Application for quotation of securities - TLX

×

Application for quotation of securities - TLX

31 January 25

Cleansing Notice

×

Cleansing Notice

31 January 25

Notification regarding unquoted securities - TLX

×

Notification regarding unquoted securities - TLX

31 January 25

Application for quotation of securities - TLX

×

Application for quotation of securities - TLX

31 January 25

Cleansing Notice

×

Cleansing Notice

28 January 25

Telix Completes Acquisition of RLS (USA) Inc

×

Telix Completes Acquisition of RLS (USA) Inc

17 January 25

Illuccix Receives European Approval

×

Illuccix Receives European Approval

13 January 25

TLX to Acquire Next-Gen Therapeutics and Biologics Platform

×

TLX to Acquire Next-Gen Therapeutics and Biologics Platform

13 January 25

Presentation to Accompany Biologics Platform Acquisition

×

Presentation to Accompany Biologics Platform Acquisition

13 January 25

Proposed issue of securities - TLX

×

Proposed issue of securities - TLX

13 January 25

Telix Exceeds FY24 Guidance with US$142M Q4 Revenue

×

Telix Exceeds FY24 Guidance with US$142M Q4 Revenue

13 January 25

Telix JP Morgan Healthcare Conference 2025 Presentation

×

Telix JP Morgan Healthcare Conference 2025 Presentation

09 January 25

Notification of cessation of securities - TLX

×

Notification of cessation of securities - TLX

30 December 24

Telix Files TLX250-CDx (Zircaix) BLA for Kidney Imaging

×

Telix Files TLX250-CDx (Zircaix) BLA for Kidney Imaging

30 December 24

Managing Director and Group CEO Remuneration Update

×

Managing Director and Group CEO Remuneration Update

13 December 24

Securities Dealing Policy - Updated

×

Securities Dealing Policy - Updated

28 November 24

Application for quotation of securities - TLX

×

Application for quotation of securities - TLX

28 November 24

Notification regarding unquoted securities - TLX

×

Notification regarding unquoted securities - TLX

TLX Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.34 0.02 0.15 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.34 0.02 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock -17.4 104.9 814.7 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A 118.8 114.7 Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A 50.6 72.7 Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.20 0.18 0.00 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.23 0.04 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock -0.1 189.1 -100.0 Lock Lock Lock
     Yield % Lock Lock Lock Lock -3.1 0.4 0.0 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A 0.0 0.0 Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.25 0.46 0.00 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.07 0.12 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 135.4 82.4 -100.0 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 311 324 0 Lock Lock Lock
Basic m Lock Lock Lock Lock 311 319 0 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 160 503 783 Lock Lock Lock
     Growth % Lock Lock Lock Lock 2,007.6 213.9 55.8 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 103 263 410 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 29 315 510 Lock Lock Lock
     Growth % Lock Lock Lock Lock 198.6 973.0 61.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock 18.3 62.6 65.1 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 82 37 35 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -68 58 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 10.9 186.2 -100.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -42.4 11.6 0.0 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 5 7 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -73 52 100 Lock Lock Lock
     Growth % Lock Lock Lock Lock 9.9 170.4 93.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock -45.7 10.3 12.7 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -99 3 0 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 5 -2 0 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -104 5 50 Lock Lock Lock
     Growth % Lock Lock Lock Lock -29.3 105.0 857.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock -65.0 1.0 6.4 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -64 24 0 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 14 11 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -17 -25 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 175 10 0 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -71 14 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -17.0 120.0 -100.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -0.4 0.0 0.0 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 116 123 710 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 261 402 0 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 10 16 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -106 -106 0 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 178 251 0 Lock Lock Lock
Equity $m Lock Lock Lock Lock 80 149 0 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 90 165 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 2,109.4 83.5 -100.0 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -39.9 1.3 N/A Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -130.1 3.5 N/A Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -153.8 40.1 0.0 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -221.7 4.1 0.0 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -136.3 18.8 0.0 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -167.0 59.0 N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.6 -1.8 N/A Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -132.3 -71.0 N/A Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 2.0 1.4 0.0 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 1.9 1.3 0.0 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 67.2 54.8 N/A Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -74.8 15.2 N/A Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 4.8 8.5 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 21.9 14.6 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 1.8 7.5 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 10.5 6.5 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.6 1.2 N/A Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.6 1.2 N/A Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -61.6 0.6 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -37.8 0.8 N/A Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 -68.8 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -39.9 1.3 N/A Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 3.3 2.7 N/A Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -130.1 3.5 N/A Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -130.1 3.5 N/A Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 16.7 25.1 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 76.1 42.8 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 92.8 67.8 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 38.6 46.1 0.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 54.2 21.8 0.0 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

.0%

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

3.27%

Value ($M)

298

Prior Change

N/A

7 Day Change

-0.10%

1 Month Change

0.10%

3 Month Change

0.30%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

TLX Shortsell

Frequently Asked Questions

The current share price of Telix Pharmaceuticals Limited (TLX:ASX) is AU$30.12.
The 52-week high share price for Telix Pharmaceuticals Limited (TLX:ASX) is AU$29.72.
The 52-week low share price for Telix Pharmaceuticals Limited (TLX:ASX)? is AU$10.34.
The current TTM dividend payout for Telix Pharmaceuticals Limited (TLX:ASX) is 0.00.
Telix Pharmaceuticals Limited (TLX:ASX) does not pay a dividend.
Telix Pharmaceuticals Limited (TLX:ASX) has a franking level of 0.0%.
Telix Pharmaceuticals Limited (TLX:ASX) is classified in the Healthcare.
The current P/E ratio for Telix Pharmaceuticals Limited (TLX:ASX) is 114.70.
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.